At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 513 enrolled
Drug / intervention
Fluoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating Fluoxetine and Placebo for Major Depressive Disorder. Completed, enrolled 513 participants across 16 sites.
Detailed Summary
The purpose of this study is to evaluate the short-term efficacy and safety of Fluoxetine in Japanese adult participants with Major Depressive Disorder (MDD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedMar 2013
Primary CompletionJul 2014
TodayJul 2026
First PostedMar 11, 2013
Enrollment StartMar 1, 2013
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.3 years ago
Interventions
Fluoxetinedrug
Placebodrug